What’s Happening at enGenome

Three Themes That Defined the First Half of 2026 for Genomics

By Ettore Rizzo, CEO, enGenome

ACMG SVC v4.0: A Significant Step Forward for Rare Disease Genomics

By Susanna Zucca, CSO, enGenome

The WGS Paradox: Why Clinical Genomics Is Advancing Faster Than Reimbursement Models

By Ettore Rizzo, CEO, enGenome

The Dark Genome and the Future of Predictive Genomics

By Susanna Zucca, CSO, enGenome

The Variant Interpretation Workforce Crisis: Genomics Is Scaling. The Experts Are Not.

By Ettore Rizzo, CEO, enGenome

The $100 Genome Debate Misses the Real Challenge: Interpretation

By Ettore Rizzo, CEO, enGenome

International day of women and girls in science

A conversation with Susanna Zucca, CSO & Co-founder of enGenome

What AlphaGenome means for genomics, and why interpretation still matters

By Susanna Zucca, CSO, enGenome

AI’s role in making rare disease diagnosis more efficient

Unveiling the stigma of genetic discrimination

Rare diseases: an overwhelming economic scenario

Artificial Intelligence regulation and the future of clinical genomics